首页> 外文期刊>JAMA: the Journal of the American Medical Association >Temporal trends in the prevalence of diabetic kidney disease in the United States.
【24h】

Temporal trends in the prevalence of diabetic kidney disease in the United States.

机译:在美国,糖尿病肾病流行的时间趋势。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Diabetes is the leading cause of kidney disease in the developed world. Over time, the prevalence of diabetic kidney disease (DKD) may increase due to the expanding size of the diabetes population or decrease due to the implementation of diabetes therapies. OBJECTIVE: To define temporal changes in DKD prevalence in the United States. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analyses of the Third National Health and Nutrition Examination Survey (NHANES III) from 1988-1994 (N = 15,073), NHANES 1999-2004 (N = 13,045), and NHANES 2005-2008 (N = 9588). Participants with diabetes were defined by levels of hemoglobin A(1c) of 6.5% or greater, use of glucose-lowering medications, or both (n = 1431 in NHANES III; n = 1443 in NHANES 1999-2004; n = 1280 in NHANES 2005-2008). MAIN OUTCOME MEASURES: Diabetic kidney disease was defined as diabetes with albuminuria (ratio of urine albumin to creatinine >/=30 mg/g), impaired glomerular filtration rate (<60 mL/min/1.73 m(2) estimated using the Chronic Kidney Disease Epidemiology Collaboration formula), or both. Prevalence of albuminuria was adjusted to estimate persistent albuminuria. RESULTS: The prevalence of DKD in the US population was 2.2% (95% confidence interval [CI], 1.8%-2.6%) in NHANES III, 2.8% (95% CI, 2.4%-3.1%) in NHANES 1999-2004, and 3.3% (95% CI, 2.8%-3.7%) in NHANES 2005-2008 (P <.001 for trend). The prevalence of DKD increased in direct proportion to the prevalence of diabetes, without a change in the prevalence of DKD among those with diabetes. Among persons with diabetes, use of glucose-lowering medications increased from 56.2% (95% CI, 52.1%-60.4%) in NHANES III to 74.2% (95% CI, 70.4%-78.0%) in NHANES 2005-2008 (P <.001); use of renin-angiotensin-aldosterone system inhibitors increased from 11.2% (95% CI, 9.0%-13.4%) to 40.6% (95% CI, 37.2%-43.9%), respectively (P <.001); the prevalence of impaired glomerular filtration rate increased from 14.9% (95% CI, 12.1%-17.8%) to 17.7% (95% CI, 15.2%-20.2%), respectively (P = .03); and the prevalence of albuminuria decreased from 27.3% (95% CI, 22.0%-32.7%) to 23.7% (95% CI, 19.3%-28.0%), respectively, but this was not statistically significant (P = .07). CONCLUSIONS: Prevalence of DKD in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among persons with diabetes, prevalence of DKD was stable despite increased use of glucose-lowering medications and renin-angiotensin-aldosterone system inhibitors.
机译:背景:糖尿病是发达国家肾脏疾病的主要原因。随着时间的流逝,糖尿病性肾脏疾病(DKD)的患病率可能因糖尿病人群的规模扩大而增加,或因实施糖尿病疗法而减少。目的:定义美国DKD患病率的时间变化。设计,地点和参与者:1988年至1994年(N = 15,073),NHANES 1999-2004年(N = 13,045)和NHANES 2005-2008年(第三次全国健康与营养检查调查(NHANES III))的横断面分析N = 9588)。糖尿病参与者的定义为血红蛋白A(1c)的水平为6.5%或更高,使用降糖药或两者兼有(NHANES III中n = 1431; NHANES 1999-2004中n = 1443; NHANES中n = 1280 2005-2008)。主要观察指标:糖尿病肾病定义为患有白蛋白尿(尿白蛋白与肌酐之比> / = 30 mg / g),肾小球滤过率受损(<60 mL / min / 1.73 m(2))的糖尿病。疾病流行病学协作公式),或两者兼而有之。调整蛋白尿的患病率以估计持续性蛋白尿。结果:在NHANES III中,美国人群中DKD的患病率为2.2%(95%置信区间[CI],1.8%-2.6%),1999-2004年在NHANES中为2.8%(95%CI,2.4%-3.1%) ,以及2005-2008年NHANES的3.3%(95%CI,2.8%-3.7%)(趋势P <.001)。 DKD的患病率与糖尿病的患病率成正比,而糖尿病患者中DKD的患病率没有变化。在糖尿病患者中,降糖药物的使用率从NHANES III中的56.2%(95%CI,52.1%-60.4%)增加到NHANES 2005-2008中的74.2%(95%CI,70.4%-78.0%)(P <.001);肾素-血管紧张素-醛固酮系统抑制剂的使用率分别从11.2%(95%CI,9.0%-13.4%)增加到40.6%(95%CI,37.2%-43.9%)(P <.001);肾小球滤过率受损的患病率分别从14.9%(95%CI,12.1%-17.8%)增加到17.7%(95%CI,15.2%-20.2%)(P = .03);蛋白尿的患病率分别从27.3%(95%CI,22.0%-32.7%)降低到23.7%(95%CI,19.3%-28.0%),但无统计学意义(P = .07)。结论:从1988年到2008年,美国DKD的患病率与糖尿病的患病率成正比。在糖尿病患者中,尽管增加了降糖药物和肾素-血管紧张素-醛固酮系统抑制剂的使用,但DKD的患病率仍然稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号